Alembic Pharma receives final US FDA approval for eye inflammation drug

January 27, 2026
Uncategorized

Alembic Pharmaceuticals said it has received final US FDA approval for its Difluprednate ophthalmic emulsion, expanding its cumulative ANDA approvals in the US market.

Alembic Pharma receives final US FDA approval for eye inflammation drug

Leave a ReplyCancel Reply

Ramkrishna Forgings Q3 Results: Margins expand, revenue up 2% on strong order book

Spandana Sphoorty Q3 | Micro lender cuts losses to ₹83 crore as NII rises 13%

Gopal Snacks posts healthy Q3; profit up 3-fold, margins double, interim dividend declared

PC Jeweller Q3 Results: Profit rises 31% on festive demand, sharp margin expansion

Mahindra Logistics Q3 Results: Turns profitable after 11 quarters as margin improves